Guangdong True Health Medical Technology Development Co., Ltd.

Guangdong True Health Medical Technology Development Co., Ltd.

2697.HK
Guangdong True Health Medical Technology Development Co., Ltd.HK flagHong Kong Stock Exchange
366.80
HKD
-14.60
- -
13.08BMarket Cap
2024 Y
2025 Y
Revenue per Share
0.05
- -
Basic EPS, GAAP
-2.59
- -
Free Cash Flow per Basic Share
-2.95
- -
Dividend per Share
- -
- -
Book Value per Share
-14.2
- -
Tangible Book Value per Share
3.48
- -
Basic Weighted Avg Shares
36
- -
Sales/Revenue/Turnover
2
12
Operating Margin (%)
-5,169.01
-749.78
Depreciation Expense
13
14
Net Income, GAAP
-92
-90
Effective Tax Rate (%)
- -
- -
Profit Margin (%)
-5,145.51
-739.97
Working Capital
89
209
LT Debt
5
3
Total Equity
125
240
Return on Invested Capital (%)
- -
- -
Return on Capital (%)
- -
- -
Return on Common Equity (%)
- -
- -

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
90.97%
Free Cash Flow
- -
- -
-9.4%
Net Income, GAAP
- -
- -
-2.22%
Sales/Revenue/Turnover
- -
- -
579.96%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
2
2025
- -
- -
- -
- -
12

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-2.59
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Hou Iam Cheong
Full Time Employees
156
Sector
Healthcare
Industry
Medical - Devices
Address
Room 101 Zhuhai GD People's Republic of China
IPO Date
Jun 30, 2026
Business
Guangdong True Health Medical Technology Development Co., Ltd. engages in the research, development, manufacturing, and sale of medical devices and health technology solutions, with ticker 2697.HK listed on the Hong Kong Exchange. The company focuses on intelligent medical hardware, interventional devices, diagnostic equipment, and related healthcare IT platforms, delivering integrated medical technology products and services for hospitals, clinics, and healthcare providers. Main products and services: high-precision imaging and diagnostic devices; minimally invasive interventional instruments and consumables; smart hospital equipment and connected health IT platforms; wound care and rehabilitation devices; consumer health tech and telemedicine solutions; sterilization and facility management solutions; medical software, data analytics, and remote monitoring services; research and development services for medical device integration; regulatory and quality assurance support offerings; after-sales service and maintenance contracts; educational and training programs for clinical adoption; firmware and hardware integration kits; modular medical device ecosystems enabling interoperability; customization and OEM/ODM manufacturing for third-party brands. Geographic and operating footprint: operates primarily within China with expansion to international markets in Asia-Pacific, Europe, and the Americas; maintains manufacturing facilities in Guangdong province; serves hospitals, clinics, healthcare distributors, and integrators across multiple regions; supports global customers through regional offices, service centers, and authorized distributors. Founding year and headquarters: founded in the early 2010s; headquarters located in Guangdong Province, China. Industry and segments: active in medical devices and health technology; segments include imaging and diagnostic devices, interventional solutions, smart hospital and IT platforms, consumer health technology, and related services. Subsidiaries and corporate structure: structured with a parent holding company and multiple subsidiaries focusing on product development, manufacturing, sales, and after-sales support; maintains affiliations with strategic partners and suppliers to enhance R&D, regulatory, and distribution capabilities. Latest major changes: recent partnerships and strategic alliances in the medical device ecosystem; recent funding rounds or acquisitions to bolster product lines and geographic reach; new product launches spanning diagnostic imaging, interventional devices, and smart hospital IT platforms; major strategic shifts toward deeper vertical integration, expanded international distribution, and enhanced regulatory approvals; corporate reorganization or name adjustments within the group to optimize operations; notable operational changes in manufacturing scale, supply chain resilience, and service network expansion within the last 1-2 years. Additional context: industry position centers on device innovation, intelligent healthcare hardware, and integrated care solutions; targets hospitals, clinics, and healthcare providers seeking high-quality diagnostic and treatment technologies; geographic operations span China and international markets, with emphasis on regions pursuing digital health and minimally invasive medical care; parent-subsidiary relationships support a broad portfolio across device categories and software platforms.